The efficacy of anti-angiogenic agents (AAAs) in epithelial ovarian cancer (EOC) remains
unclear. Therefore, we conducted a systematic review and network meta-analysis (NMA) to …

Bevacizumab is the first antiangiogenic agent to have demonstrated benefit as first-line and
maintenance therapy in epithelial ovarian cancer (EOC), with the Gynecologic Oncology …

The impact of bevacizumab (an anti-vascular endothelial growth factor therapy) remains
uncertain, which has been the focus of studies on the management of epithelial ovarian …

Background Angiogenesis inhibitors showed activity in ovarian cancer, but preliminary data
could not accurately reflect the survival benefit. We thus did a systematic review and meta …

Platinum and taxane-based chemotherapy after surgical cytoreduction remains the mainstay
of treatment for advanced ovarian malignancies, with median progression-free survival …

Objective The value of antiangiogenic inhibitors for patients with recurrent ovarian cancer
has not been completely affirmed. Therefore, we aimed to assess the effectiveness and …

Objectives The optimal systemic therapy strategy for advanced epithelial ovarian cancer
(EOC) remains unclear. We performed a systematic review and meta-analysis to assess …

Objective To investigate the efficacy and safety of angiogenesis inhibitors in the treatment of
recurrent ovarian cancer (OC). Methods Electronic databases including PubMed, Web of …

Background To analyze the efficacy and toxicity of bevacizumab on survival outcomes in
recurrent ovarian cancer. Results Bevacizumab was associated with significant …

High-grade epithelial ovarian cancer (HG-EOC) is the most lethal gynecologic malignancy
worldwide Once patients develop chemoresistance, effective novel strategies are required to …